Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
Lopez
M
M
Di Lauro
L
L
Papaldo
P
P
Ganzina
F
F
Di Pietro
N
N
Lazzaro
B
B
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D015255:Idarubicin; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin